The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2019The Synaptic Vesicle Cycle in Parkinson’s Disease
Study Rationale:
Many of the proteins implicated in Parkinson’s disease appear to have a role at the nerve terminal, presumably in neurotransmitter release. However, the function of most has remained... -
GBA Biology and Therapies, 2019Expression of GCase throughout Brain Vasculature for Degradation of Alpha-synuclein Aggregates
Study Rationale:
Alpha-synuclein toxicity is caused by progressive accumulation of this protein in cells. Alpha-synuclein protein aggregation is helped along by impaired lysosomes... -
Research Grant, 2019Validation of Microglial CRAC Channels as a Therapeutic Target for Parkinson’s Disease
Study Rationale:
Inflammation of the central nervous system mediated by microglial cells is a major feature of Parkinson’s disease. Vivreon Biosciences is developing Parkinson’s disease therapeutics... -
Research Grant, 2019Determining the Level of LRRK2 Inhibition Required for Therapeutic Efficacy
Study Rationale:
While inhibitors of LRRK2 activity are currently in clinical trials for the treatment of Parkinson’s disease, the minimum requirement of target engagement to significantly modify... -
Therapeutic Pipeline Program, 2019Mapping Brain Response Patterns to Deep Brain Stimulation with FMRI
Study Rationale:
Deep brain stimulation (DBS) targets malfunctioning brain circuits. Commonly used to treat Parkinson’s disease (PD), this surgical therapy can produce striking clinical benefits when... -
Epidemiological Parkinson's Risk Modifiers, 2019Study in Norwegian Population to Identify Therapies with Repurposing Potential for Parkinson’s Disease
Study Rationale:
There are not yet medicines that can prevent or slow Parkinson’s disease. Developing a new therapeutic can cost up to 2.6 billion dollars and takes many years of screening, chemistry...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.